ArticleNature biomedical engineering2026
Phenotypic prediction of missense variants via deep contrastive learning.
Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Missense variants (MVs) influence clinical phenotypes, but our understanding of their phenotypic consequences remains constrained. Existing computational approaches to interpret MVs predominantly assess their pathogenicity, without considering phenotypic heterogeneity. We present a machine-learning-based method, PheMART, to predict the clinical phenotypic consequences of MVs. PheMART integrates comprehensive variant and phenotype characterizations by leveraging a robust combination of multiple resources involving protein language models, protein-protein interactions, protein domains, medical knowledge graphs and electronic health records. Exploiting contrastive learning, PheMART establishes connections between MVs and 4,179 phenotypes by jointly projecting them into a cohesive low-dimensional metric space where proximity signifies relevance. Besides substantially outperforming existing models, PheMART aids in diagnosing individuals with rare diseases by effectively pinpointing clinical diagnoses and causative MVs. As a resource to the community, we provide a database of phenotypic predictions for 5.1 million putative pathogenic amino acid alterations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.